Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-12
2005-04-12
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C514S252050, C544S238000, C544S240000
Reexamination Certificate
active
06878709
ABSTRACT:
Disclosed are compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
REFERENCES:
patent: 4170588 (1979-10-01), Hegenberg et al.
patent: 4639523 (1987-01-01), Nohara et al.
patent: 5206252 (1993-04-01), Butera et al.
patent: 5354763 (1994-10-01), Butera et al.
patent: 5397790 (1995-03-01), Butera et al.
patent: 5401753 (1995-03-01), Butera et al.
patent: 5403853 (1995-04-01), Butera et al.
patent: 5466712 (1995-11-01), Butera et al.
patent: 5506252 (1996-04-01), Butera et al.
patent: 5532245 (1996-07-01), Butera et al.
patent: 5840764 (1998-11-01), Quagliato et al.
patent: 6300325 (2001-10-01), Widdowson et al.
patent: 6376555 (2002-04-01), Butera et al.
patent: 6420396 (2002-07-01), Albers et al.
patent: 20010018447 (2001-08-01), Widdowson et al.
patent: 33 09 655 (1984-09-01), None
patent: 0 099 121 (1984-01-01), None
patent: 0 275 997 (1988-07-01), None
patent: 0 376 079 (1990-07-01), None
patent: 0 796 243 (1999-01-01), None
patent: 1186096 (1970-04-01), None
patent: WO 9429277 (1994-12-01), None
patent: WO 9514005 (1995-05-01), None
patent: WO 9614300 (1996-05-01), None
patent: WO 9615103 (1996-05-01), None
patent: WO 9833763 (1998-08-01), None
patent: WO 0020378 (2000-04-01), None
patent: WO 0021927 (2000-04-01), None
patent: WO 0035855 (2000-06-01), None
patent: WO 0035864 (2000-06-01), None
patent: WO 0073260 (2000-12-01), None
patent: WO 0129000 (2001-04-01), None
patent: WO 0164208 (2001-09-01), None
patent: WO 0164691 (2001-09-01), None
patent: WO 0168569 (2001-09-01), None
patent: WO 0192202 (2001-12-01), None
patent: WO 02057230 (2002-07-01), None
patent: WO 02067919 (2002-09-01), None
patent: WO 02076926 (2002-10-01), None
patent: WO 02083624 (2002-10-01), None
patent: WO 03057676 (2003-07-01), None
patent: WO 03080053 (2003-10-01), None
Karady, Sandor, et al., “1,2,5-Thiadiazole-1-Oxides.I.Synthesis and Reactions of Alkoxy and Alkylthio Analogs,”Heterocycles16(9):1561-4 (1981).
Martinez, Ana, et al., “Synthesis of nonsymmetrically 3,4-disubstituted 1,2,5-thiadiazole dioxides,”Journal of Heterocyclic Chemistry35(2):297-300 (1998).
Neuse, Eberhard W., et al., “Poly(squaryl amides)”Polymer15:339-45 (1974).
Patent Abstracts of Japan, vol. 018, No. 361 (c-1222), Jul. 7, 1994 and JP 06 092915A, Apr. 5, 1994 abstract.
Schostarez, Heinrich J., et al., “Cyanoguanidine bioisosteres in potassium channel openers: evaluation 3,4-disubstituted-1,2,5-thiadiazole-1-oxides,”Bioorganic&Medicinal Chemistry Letters6(18):2187-92 (1996).
Wen, Richard Y., et al. “The Chemistry of 1,2,5-Thiadiazoles. II.3,5-Disubstituted Derivatives of 1,2,5-Thiadiazole, 1,1-Dioxide,”J. Org. Chem.40(19):2743-8 (1975).
Zhou, Hai-Bing, et al., “Design, synthesis and structure of new chiral squaric acid monoaminoalcohls and diaminoalcohols and their use as catalysts in asymmetric reduction of ketones and diketones,”Tetrahedron57:9325-9333 (2001).
U.S. Pub. No. 2003/0204085 [Oct. 30, 2003] for Serial No. 10/208,426 filed Jul. 30, 2002.
U.S. Pub. No. 2004/0034229 [Feb. 19, 2004] for Serial No. 10/269,775 filed Oct. 11, 2002.
U.S. Appl. No. 10/335,789, filed Jan. 2, 2003.
U.S. Appl. No. 10/390,078, filed Mar. 17, 2003.
U.S. Appl. No. 10/630,258, filed Jul. 30, 2003.
U.S. Appl. No. 10/680,393, filed Oct. 7, 2003.
PCT International Search Report dated May 22, 2003 for corresponding PCT Application No. PCT/US03/00299.
esp#cenet Document, “1,2,5-Thiadiazole-1-oxides and 1,1-dioxides, process for their preparation and their use as medicaments” (for DE3309655 which is attached to said esp document).
Chemical Abstract 66:18527 for Maahs, Guenther, et al., “Syntheses and derivatives of squaric acid,”Angewandte Chemie78:(20):927-31 (1966) (which is attached to said abstract).
Chemical Abstract 87:134383 for Augustin Manfred, et al., “Disubstitution in 2,3-dichloromaleimides”Zeitschrift Fuer Chemie17(6):215-216 (1977) (which is attached to said abstract).
Chemical Abstract No. 87:151727 for Ebrhardt, Heinz, et al., “Amides and thloamides of squaric acid: syntheses and reactions,”Chemische Berichte110(7):2506-23 (1977) (which is attached to said abstract).
Chemical Abstract 102:24633 for Stegelmeier, Hartmut, et al., “1,2,5-Thiadiazole-1-oxide and 1,1-dioxides and their use as pharmaceuticals” (for DE3309655 which is attached to said abstract).
Chemical Abstract 104:129517 for Gruenefeld, Johann, et al., “Reactions of squaric acid with carbodiimides,”Archiv der Pharmazie318(12):1062-70 (1985) (which is attached to said abstract).
Chemical Abstract No. 122:160745 for Tillack, Annegret, et al., “Assymmetric catalysis. IV. Hydrosilylation of acetophenone with pyrroline-2,5-dione modified [Rh(COD)C1]2 catalyst,”Journal of Organometallic Chemistry482:85-91 (1994) (which is attached to said abstract).
Chemical Abstract No. 125:300482 for Chen, Yizhao, et al., “Reaction of dibutyl oxosquarate with aromatic primary amines,”Sichuan Daxue Xuebao, Ziran Kexueban33(2):182-186 (1996) (which is attached to said abstract).
Chemical Abstract No. 130:222994 for Chen, Yi-Zhao, et al., “Synthesis of asymmetric aryl-substituted amides of squaric acid and asymmetric isosquarylium amides,”Hechen Huaxue6(4):383-392 (1998) (which is attached to said abstract).
Butera, John A., et al., “Design and SAR of Novel Potassium Channel Openers Targeted to Urge Urinary Incontinence. 1. N-Cyanoguanidine Bioisoteres Possessing in Vivo Bladder Selectivity,”J. Med. Chem.43:1187-1202 (2000).
Davis, Peter D., et al., “Inhibitors of protein kinase C 1,2,3-Bisarylmaleimides,”J. Med. Chem.35:177-184 (1992).
Hanaineh-Abdelnour, Leila, et al., “Some synthetic applications of 2,3-Dichloro-N-phenylmaleimide: A Novel Synthesis of 2-Phenylpyrrolo[3,4-b]quinoxaline-1,3-diones. 1,”Tetrahedron55:11859-11870 (1999).
Hoffman, Jacob M., et al., “Conformational Requirements of Histamine H2-Receptor Inhibitors: A Structure-Activity Study of Phenylene Analogues Related to Cimetidine and Tiotidine,”Journal of Medicinal Chemistry26(2):140-44 (1983).
Baldwin John J.
Chao Jianhua
Chao Jianping
Dwyer Michael
Li Ge
Bernhardt Emily
Jeanette Henry C.
Pharmacopeia Drug Discovery Inc.
Schering Corporation
LandOfFree
3,4-di-substituted pyridazinediones as CXC chemokine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,4-di-substituted pyridazinediones as CXC chemokine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-di-substituted pyridazinediones as CXC chemokine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3422790